<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15777968</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>07</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0169-5002</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>48</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Lung cancer (Amsterdam, Netherlands)</Title>
                <ISOAbbreviation>Lung Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE).</ArticleTitle>
            <Pagination>
                <MedlinePgn>19-29</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Malignant pleural mesothelioma (MPM) is a fatal neoplasm with no acceptable curative approaches. We used serial analysis of gene expression (SAGE) to compare the gene expression pattern of a surgically resected MPM to the autologous normal mesothelium. Intelectin gene overexpression (&gt;139-fold) was found in the tumor. Online SAGE datasets revealed intelectin to be consistently present in mesothelioma(s), ovarian cancer, and colon cancer. Intelectin mRNA expression was found by RT-PCR in 4 of 5 resected MPM tumors, and Intelectin protein expression was confirmed by immunohistochemistry in 28 of 53 MPM tumors, and in 4 of 4 mesothelioma cell lines studied by Western blot. A marked induction in intelectin gene expression was observed among human primary mesothelial cells as a consequence of crocidolite asbestos exposure and simian virus 40 infection. Intelectin overexpression in mesothelioma could have potential screening, and therapeutic implications.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wali</LastName>
                    <ForeName>Anil</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Oncology Program, Karmanos Cancer Institute, and John D. Dingell VA Medical Center, Wayne State University, 3990 John R, Suite 2102, Detroit, MI 48201, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morin</LastName>
                    <ForeName>Patrice J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hough</LastName>
                    <ForeName>Colleen D</ForeName>
                    <Initials>CD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lonardo</LastName>
                    <ForeName>Fulvio</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seya</LastName>
                    <ForeName>Tsukasa</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carbone</LastName>
                    <ForeName>Michele</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pass</LastName>
                    <ForeName>Harvey I</ForeName>
                    <Initials>HI</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2004</Year>
                <Month>12</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Lung Cancer</MedlineTA>
            <NlmUniqueID>8800805</NlmUniqueID>
            <ISSNLinking>0169-5002</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C432397">ITLN1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D037102">Lectins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>12001-28-4</RegistryNumber>
                <NameOfSubstance UI="D017638">Asbestos, Crocidolite</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017638">Asbestos, Crocidolite</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D030541">Databases, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058851">GPI-Linked Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D037102">Lectins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008654">Mesothelioma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010997">Pleural Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D027601">Polyomavirus Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014412">Tumor Virus Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2004</Year>
                <Month>7</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2004</Year>
                <Month>10</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2004</Year>
                <Month>10</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2004</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>7</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0169-5002(04)00531-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.lungcan.2004.10.011</ArticleId>
            <ArticleId IdType="pubmed">15777968</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15679473</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>01</Month>
            <Day>31</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1742-7835</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>96</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Basic &amp; clinical pharmacology &amp; toxicology</Title>
                <ISOAbbreviation>Basic Clin. Pharmacol. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of trimedoxime in mice poisoned with dichlorvos, heptenophos or monocrotophos.</ArticleTitle>
            <Pagination>
                <MedlinePgn>111-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The aim of the study was to examine antidotal potency of trimedoxime in mice poisoned with three direct dimethoxy-substituted organophosphorus inhibitors. In order to assess the protective efficacy of trimedoxime against dichlorvos, heptenophos or monocrotophos, median effective doses and efficacy half-times were calculated. Trimedoxime (24 mg/kg intravenously) was injected 5 min. before 1.3 LD50 intravenously of poisons. Activities of brain, diaphragmal and erythrocyte acetylcholinesterase, as well as of plasma carboxylesterases were determined at different time intervals (10, 40 and 60 min.) after administration of the antidotes. Protective effect of trimedoxime decreased according to the following order: monocrotophos &gt; heptenophos &gt; dichlorvos. Administration of the oxime produced a significant reactivation of central and peripheral acetylcholinesterase inhibited with dichlorvos and heptenophos, with the exception of erythrocyte acetylcholinesterase inhibited by heptenophos. Surprisingly, trimedoxime did not induce reactivation of monocrotophos-inhibited acetylcholinesterase in any of the tissues tested. These organophosphorus compounds produced a significant inhibition of plasma carboxylesterase activity, while administration of trimedoxime led to regeneration of the enzyme activity. The same dose of trimedoxime assured survival of experimental animals poisoned by all three organophosphorus compounds, although the biochemical findings were quite different.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Antonijević</LastName>
                    <ForeName>Biljana</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Toxicological Chemistry, School of Pharmacy, University of Belgrade, Vojvode Stepe 450, Serbia and Montenegro. abiljana@pharmacy.bg.ac.yu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bokonjić</LastName>
                    <ForeName>Dubravko</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stojiljković</LastName>
                    <ForeName>Milos P</ForeName>
                    <Initials>MP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kilibarda</LastName>
                    <ForeName>Vesna</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Milovanović</LastName>
                    <ForeName>Zoran A</ForeName>
                    <Initials>ZA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nedeljković</LastName>
                    <ForeName>Mirjana</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maksimović</LastName>
                    <ForeName>Matej</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Denmark</Country>
            <MedlineTA>Basic Clin Pharmacol Toxicol</MedlineTA>
            <NlmUniqueID>101208422</NlmUniqueID>
            <ISSNLinking>1742-7835</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010091">Oximes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>34783-40-9</RegistryNumber>
                <NameOfSubstance UI="C014022">heptenophos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>56-97-3</RegistryNumber>
                <NameOfSubstance UI="D014289">Trimedoxime</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6923-22-4</RegistryNumber>
                <NameOfSubstance UI="D008999">Monocrotophos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7U370BPS14</RegistryNumber>
                <NameOfSubstance UI="D004006">Dichlorvos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.1</RegistryNumber>
                <NameOfSubstance UI="D043182">Carboxylesterase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N9YNS0M02X</RegistryNumber>
                <NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000109">Acetylcholine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001923">Brain Chemistry</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043182">Carboxylesterase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003964">Diaphragm</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004006">Dichlorvos</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004353">Drug Evaluation, Preclinical</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004912">Erythrocytes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007275">Injections, Intravenous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007928">Lethal Dose 50</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008999">Monocrotophos</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D062025">Organophosphate Poisoning</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009943">Organophosphorus Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010091">Oximes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014289">Trimedoxime</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">PTOpto960204</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1742-7843.2005.pto960204.x</ArticleId>
            <ArticleId IdType="pubmed">15679473</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14695733</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>12</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>02</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-3022</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>100</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anesthesiology</Title>
                <ISOAbbreviation>Anesthesiology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences.</ArticleTitle>
            <Pagination>
                <MedlinePgn>120-33</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Morphine-6-glucuronide (M6G) is a metabolite of morphine and a micro-opioid agonist. To quantify the potency and speed of onset-offset of M6G and explore putative sex dependency, the authors studied the pharmacokinetics and pharmacodynamics of M6G in volunteers using a placebo-controlled, randomized, double-blind study design.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Ten men and 10 women received 0.3 mg/kg intravenous M6G and placebo (two thirds of the dose as bolus, one third as a continuous infusion over 1 h) on separate occasions. For 7 h, pain tolerance was measured using gradually increasing transcutaneous electrical stimulation, and blood samples were obtained. A population pharmacokinetic (inhibitory sigmoid Emax)-pharmacodynamic analysis was used to analyze M6G-induced changes in tolerated stimulus intensity. The improvement in model fits by inclusion of covariate sex was tested for significance. P values less than 0.01 were considered significant. Taking into account previous morphine data, a predictive pharmacokinetic-pharmacodynamic model was constructed to determine the contribution of M6G to morphine analgesia.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">M6G concentrations did not differ between men and women. M6G caused analgesia significantly greater than that observed with placebo (P &lt; 0.01). The M6G analgesia data were well described by the pharmacokinetic-pharmacodynamic model. The M6G effect site concentration causing a 25% increase in current (C25) was 275 +/- 135 nm (population estimate +/- SE), the blood effect site equilibration half-life was 6.2 +/- 3.3 h, and the steepness parameter was 0.71 +/- 0.18. Intersubject variability was 167% for C25 and 218% for the effect half-life. None of the model parameters showed sex dependency.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A cumulative dose of 0.3 mg/kg M6G, given over 1 h, produces long-term analgesia greater than that observed with placebo, with equal dynamics (potency and speed of onset-offset) in men and women. Possible causes for the great intersubject response variability, such as genetic polymorphism of the micro-opioid receptor and placebo-related phenomena, are discussed. The predictive pharmacokinetic-pharmacodynamic model was applied successfully and was used to estimate M6G analgesia after morphine in patients with normal and impaired renal function.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Romberg</LastName>
                    <ForeName>Raymonda</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anesthesiology, Leiden University Medical Center, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olofsen</LastName>
                    <ForeName>Erik</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sarton</LastName>
                    <ForeName>Elise</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>den Hartigh</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taschner</LastName>
                    <ForeName>Peter E M</ForeName>
                    <Initials>PE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dahan</LastName>
                    <ForeName>Albert</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Anesthesiology</MedlineTA>
            <NlmUniqueID>1300217</NlmUniqueID>
            <ISSNLinking>0003-3022</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009022">Morphine Derivatives</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017450">Receptors, Opioid, mu</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>20290-09-9</RegistryNumber>
                <NameOfSubstance UI="C018108">morphine-3-glucuronide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>20290-10-2</RegistryNumber>
                <NameOfSubstance UI="C035349">morphine-6-glucuronide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>76I7G6D29C</RegistryNumber>
                <NameOfSubstance UI="D009020">Morphine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000465">Algorithms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000698">Analgesia</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000701">Analgesics, Opioid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019540">Area Under Curve</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001499">Bayes Theorem</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004558">Electric Stimulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007262">Infusions, Intravenous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009020">Morphine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009022">Morphine Derivatives</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010147">Pain Measurement</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017450">Receptors, Opioid, mu</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012727">Sex Characteristics</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>12</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>2</Month>
                <Day>3</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>12</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14695733</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7556332</PMID>
        <DateCreated>
            <Year>1995</Year>
            <Month>11</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1995</Year>
            <Month>11</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0340-6199</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>154</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1995</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pediatrics</Title>
                <ISOAbbreviation>Eur. J. Pediatr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ceftriaxone-associated gallbladder lithiasis in children.</ArticleTitle>
            <Pagination>
                <MedlinePgn>590</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Stabile</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrara</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marietti</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maresca</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>GERMANY</Country>
            <MedlineTA>Eur J Pediatr</MedlineTA>
            <NlmUniqueID>7603873</NlmUniqueID>
            <ISSNLinking>0340-6199</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002511">Cephalosporins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75J73V1629</RegistryNumber>
                <NameOfSubstance UI="D002443">Ceftriaxone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001424">Bacterial Infections</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001996">Bronchopneumonia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002443">Ceftriaxone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002511">Cephalosporins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002769">Cholelithiasis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014552">Urinary Tract Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1995</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1995</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1995</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7556332</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10565048</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>01</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>01</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0301-2603</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>27</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>No shinkei geka. Neurological surgery</Title>
                <ISOAbbreviation>No Shinkei Geka</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[A state of confusion following cerebral angiography with iopamidol: a case report].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1027-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A 59-year-old male in a state of confusion following cerebral angiography with iopamidol was reported. He was admitted to our hospital for right upper monoparesis. MRI demonstrated multiple cerebral infarction. The patient had undergone angiographies with iopamidol, of which a total of 100 ml had been used. After the examination, the patient showed perseveration, continuing to say the same sentence and 30 minutes later he entered a state of confusion. He recovered completely from this consciousness disturbance after 30 hours. No lesion except for the old infarction was demonstrated on CT and MRI. Confusion in this case was assumed to be a toxic reaction caused by the contrast agent.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Onizuka</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Ikuwakai Memorial Hospital, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bun</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>jpn</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>JAPAN</Country>
            <MedlineTA>No Shinkei Geka</MedlineTA>
            <NlmUniqueID>0377015</NlmUniqueID>
            <ISSNLinking>0301-2603</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JR13W81H44</RegistryNumber>
                <NameOfSubstance UI="D007479">Iopamidol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D002533">Cerebral Angiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003244">Consciousness Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003287">Contrast Media</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007479">Iopamidol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>11</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10565048</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15910805</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>05</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>07</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0014-2999</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>514</Volume>
                    <Issue>2-3</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>May</Month>
                        <Day>9</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pharmacology</Title>
                <ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>alpha2-Adrenoceptor subsensitivity in mesenteric vascular bed of cholestatic rats: the role of nitric oxide and endogenous opioids.</ArticleTitle>
            <Pagination>
                <MedlinePgn>183-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Cholestasis is associated with vascular changes and in previous studies decreased response of visceral vessels of cholestatic animals to phenylephrine and acetylcholine has been shown. In the present study, the response of mesenteric vascular bed of cholestatic rats to clonidine (an alpha2-adrenoceptor agonist) was investigated and we also examined the role of endogenous opioids and nitric oxide (NO). Seven-day ligation of bile duct was used as the model to study cholestasis. Six groups of rats, each of which divided into two subgroups (bile duct-ligated and sham-operated), were examined. Three groups of animals were chronically treated with either normal saline, naltrexone (an opioid receptor antagonist, 20 mg/kg/day, s.c.) or aminoguanidine (a selective inducible nitric oxide synthase inhibitor, 150 mg/kg/day, s.c.) for 7 days. After 7 days the response of the mesenteric vascular bed to subsequent doses of clonidine was studied. In other two groups, 7 days after the operation, the response of the mesenteric vascular bed to clonidine in the presence of either yuhimbine, an alpha2-adrenoceptor antagonist, or N(omega)-nitro-L-arginine methyl ester (L-NAME), a non-selective nitric oxide synthase inhibitor, was studied. In the last group, vasodilation response to sodium nitroprusside (an endothelium-independent vasorelaxant) was evaluated. Clonidine caused vasodilation in a dose-dependent manner by acting on endothelial alpha2-adrenoceptors since its effect was antagonized by yohimbine, and this vasodilation was through the L-arginine pathway since there was no response in the presence of L-NAME in the perfusate. Compared to sham-operated rats, there was a significant right shift in the clonidine concentration curves of cholestatic animals. Maximum response in cholestatic rats was significantly lower comparing to the sham group (P&lt;0.01) and the dose of clonidine that causes 50% of maximum response (ED50) was significantly higher in cholestatic rats (P&lt;0.05). Vasodilation response to sodium nitroprusside was the same in cholestatic and sham-operated rats. Seven-day treatment with aminoguanidine recovered the effect of cholestasis. Seven-day treatment with naltrexone caused an increase in maximum response (P&lt;0.01) and a decrease in ED50 (P&lt;0.05) in cholestatic rats, while this treatment in sham-operated rats caused a decrease in the maximum response (P&lt;0.01) and an increase in ED50 (P&lt;0.05). This study showed that cholestasis is associated with decreased responsiveness of mesenteric vascular bed to clonidine and the cholestasis-associated NO overproduction and increased level of endogenous opioids may contribute to this process.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Borhani</LastName>
                    <ForeName>Amir Ali</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Houshmand</LastName>
                    <ForeName>Golbahar</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samini</LastName>
                    <ForeName>Morteza</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Namiranian</LastName>
                    <ForeName>Khodadad</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hajrasouliha</LastName>
                    <ForeName>Amir Reza</ForeName>
                    <Initials>AR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tavakoli</LastName>
                    <ForeName>Sina</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ebrahimi</LastName>
                    <ForeName>Farzad</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dehpour</LastName>
                    <ForeName>Ahmad Raza</ForeName>
                    <Initials>AR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Eur J Pharmacol</MedlineTA>
            <NlmUniqueID>1254354</NlmUniqueID>
            <ISSNLinking>0014-2999</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D058647">Adrenergic alpha-2 Receptor Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D058669">Adrenergic alpha-2 Receptor Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000317">Adrenergic alpha-Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006146">Guanidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009292">Narcotic Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018847">Opioid Peptides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018341">Receptors, Adrenergic, alpha-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>169D1260KM</RegistryNumber>
                <NameOfSubstance UI="D009599">Nitroprusside</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2Y49VWD90Q</RegistryNumber>
                <NameOfSubstance UI="D015016">Yohimbine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>31C4KY9ESH</RegistryNumber>
                <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5S6W795CQM</RegistryNumber>
                <NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.39</RegistryNumber>
                <NameOfSubstance UI="D019001">Nitric Oxide Synthase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MN3L5RMN02</RegistryNumber>
                <NameOfSubstance UI="D003000">Clonidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>RFM9X3LJ49</RegistryNumber>
                <NameOfSubstance UI="D001663">Bilirubin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SCQ4EZQ113</RegistryNumber>
                <NameOfSubstance UI="C004479">pimagedine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>V55S2QJN2X</RegistryNumber>
                <NameOfSubstance UI="D019331">NG-Nitroarginine Methyl Ester</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058647">Adrenergic alpha-2 Receptor Agonists</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058669">Adrenergic alpha-2 Receptor Antagonists</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000316">Adrenergic alpha-Agonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000317">Adrenergic alpha-Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001663">Bilirubin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002779">Cholestasis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003000">Clonidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006146">Guanidines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008638">Mesenteric Arteries</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008643">Mesentery</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019331">NG-Nitroarginine Methyl Ester</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009271">Naltrexone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009292">Narcotic Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019001">Nitric Oxide Synthase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009599">Nitroprusside</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018847">Opioid Peptides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018341">Receptors, Adrenergic, alpha-2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014664">Vasodilation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014665">Vasodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015016">Yohimbine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2004</Year>
                <Month>8</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>5</Month>
                <Day>25</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>5</Month>
                <Day>25</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-2999(05)00294-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejphar.2005.03.015</ArticleId>
            <ArticleId IdType="pubmed">15910805</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21097689</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>01</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>06</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1078-0432</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>17</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Jan</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn>286-93</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-10-1030</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Nitric oxide-donating acetylsalicylic acid (NO-ASA) has been shown to possess an antineoplastic effect in Wnt-/β-catenin-active cancers. As chronic lymphocytic leukemia (CLL) cells exhibit aberrantly active Wnt signaling, we investigated the effect of the para-isomer of NO-ASA on CLL cell survival in vitro and in a CLL-like xenograft mouse model.</AbstractText>
                <AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">Apoptosis in primary CLL cells was determined by flow cytometric annexin V-FITC (fluorescein isothiocyanate)/PI (propidium iodide) staining and immunoblotting of caspases, poly(ADP-ribose) polymerase (PARP), and antiapoptotic proteins. Interference of NO-ASA with Wnt/β-catenin signaling was analyzed through immunoblots of different pathway members. Influence of caspase activation was investigated by pretreatment with a pan-caspase inhibitor. CLL-like JVM3 cells were subcutaneously inoculated into irradiated nude mice that were treated with 100 mg of para-NO-ASA/kg of body weight p.o. (by mouth) for 21 days.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">para-NO-ASA induced apoptosis in CLL cells with an LC(50) (lethal concentration) of 8.72 + 0.04 μmol/L, whereas healthy blood cells were not affected. Furthermore, the compound induced caspase 9, caspase 3, and PARP cleavage. In addition, cleavage of β-catenin and downregulation of β-catenin/lymphoid enhancer factor (Lef)-1 targets was observed. para-NO-ASA demonstrated strong antitumor efficacy in the xenograft mouse model with a tumor inhibtion rate of 83.4%. During therapy, no gross toxicity could be observed.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">para-NO-ASA selectively induces apoptosis in primary CLL cells and efficiently reduces tumor growth in a CLL-like xenograft model. As NO-ASA is orally available and is generally well tolerated, para-NO-ASA might be a promising new compound for CLL therapy.</AbstractText>
                <CopyrightInformation>©2010 AACR.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Razavi</LastName>
                    <ForeName>Regina</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department I of Internal Medicine, Center for Integrated Oncology, University at Cologne, Cologne, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gehrke</LastName>
                    <ForeName>Iris</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gandhirajan</LastName>
                    <ForeName>Rajesh Kumar</ForeName>
                    <Initials>RK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poll-Wolbeck</LastName>
                    <ForeName>Simon Jonas</ForeName>
                    <Initials>SJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hallek</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kreuzer</LastName>
                    <ForeName>Karl-Anton</ForeName>
                    <Initials>KA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497573">LEF1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051821">Lymphoid Enhancer-Binding Factor 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020030">Nitric Oxide Donors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.22.-</RegistryNumber>
                <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R16CO5Y76E</RegistryNumber>
                <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001241">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020169">Caspases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015451">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051821">Lymphoid Enhancer-Binding Factor 1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020030">Nitric Oxide Donors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1078-0432.CCR-10-1030</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-1030</ArticleId>
            <ArticleId IdType="pubmed">21097689</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9300303</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1045-3873</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>1997</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cardiovascular electrophysiology</Title>
                <ISOAbbreviation>J. Cardiovasc. Electrophysiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Reproducible induction of &quot;atypical&quot; torsades de pointes by programmed electrical stimulation: a novel form of sotalol-induced proarrhythmia?</ArticleTitle>
            <Pagination>
                <MedlinePgn>1055-61</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We present a patient with sotalol-induced polymorphic ventricular tachycardia that was seen only with programmed ventricular stimulation. Electrophysiologic studies performed prior to initiation of sotalol therapy revealed inducible monomorphic ventricular tachycardia. Possible underlying electrophysiologic mechanisms are discussed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Krishnan</LastName>
                    <ForeName>S C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Massachusetts General Hospital, Boston 02114, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Galvin</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McGovern</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garan</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruskin</LastName>
                    <ForeName>J N</ForeName>
                    <Initials>JN</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Cardiovasc Electrophysiol</MedlineTA>
            <NlmUniqueID>9010756</NlmUniqueID>
            <ISSNLinking>1045-3873</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A6D97U294I</RegistryNumber>
                <NameOfSubstance UI="D013015">Sotalol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000889">Anti-Arrhythmia Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002304">Cardiac Pacing, Artificial</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004558">Electric Stimulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013015">Sotalol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017180">Tachycardia, Ventricular</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016171">Torsades de Pointes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1997</Year>
                <Month>9</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1997</Year>
                <Month>9</Month>
                <Day>23</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1997</Year>
                <Month>9</Month>
                <Day>23</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9300303</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15738379</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-9926</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>165</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Feb</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of internal medicine</Title>
                <ISOAbbreviation>Arch. Intern. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bortezomib-induced severe hepatitis in multiple myeloma: a case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>464-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its toxicity is manageable, and the most frequent adverse effects mainly consist of gastrointestinal symptoms, peripheral neuropathy, neuropatic pain, and thrombocytopenia. Severe liver toxicity has not been previously recognized. A patient with relapsed multiple myeloma who developed bortezomib-induced severe recurrent hepatitis is described. The importance of recognizing this rare potential toxicity is highlighted in order to discontinue this agent if liver adverse reaction is suspected.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rosiñol</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hematology Department, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Hospital Clínic, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montoto</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cibeira</LastName>
                    <ForeName>Maria Teresa</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bladé</LastName>
                    <ForeName>Joan</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Arch Intern Med</MedlineTA>
            <NlmUniqueID>0372440</NlmUniqueID>
            <ISSNLinking>0003-9926</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001897">Boronic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>69G8BD63PP</RegistryNumber>
                <NameOfSubstance UI="C400082">bortezomib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.1.1.27</RegistryNumber>
                <NameOfSubstance UI="D007770">L-Lactate Dehydrogenase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.6.1.1</RegistryNumber>
                <NameOfSubstance UI="D001219">Aspartate Aminotransferases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.6.1.2</RegistryNumber>
                <NameOfSubstance UI="D000410">Alanine Transaminase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000410">Alanine Transaminase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001219">Aspartate Aminotransferases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001897">Boronic Acids</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056487">Drug-Induced Liver Injury, Chronic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007770">L-Lactate Dehydrogenase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011480">Protease Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011719">Pyrazines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">165/4/464</ArticleId>
            <ArticleId IdType="doi">10.1001/archinte.165.4.464</ArticleId>
            <ArticleId IdType="pubmed">15738379</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">938175</PMID>
        <DateCreated>
            <Year>1976</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1976</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-9926</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>136</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1976</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of internal medicine</Title>
                <ISOAbbreviation>Arch. Intern. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Respiratory paralysis during treatment of hypertension with trimethaphan camsylate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>816-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Four cases are reported in which respiratory arrest occured coincident with the intravenous administration of large doses of trimethaphan camsylate (Arfonad) to control hypertension. The mechanism of the respiratory depression is unknown, but it may have been related to a direct effect of trimethaphan on the respiratory center or to a curare-like effect of the drug. Close monitoring of ventilatory capacity should be maintained in all patients treated with trimethaphan.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dale</LastName>
                    <ForeName>R C</ForeName>
                    <Initials>RC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schroeder</LastName>
                    <ForeName>E T</ForeName>
                    <Initials>ET</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Arch Intern Med</MedlineTA>
            <NlmUniqueID>0372440</NlmUniqueID>
            <ISSNLinking>0003-9926</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>6G8X656T45</RegistryNumber>
                <NameOfSubstance UI="D014294">Trimethaphan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000437">Alcoholism</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001014">Aortic Aneurysm</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006975">Hypertension, Portal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006977">Hypertension, Renal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007263">Infusions, Parenteral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012133">Respiratory Paralysis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014294">Trimethaphan</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1976</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1976</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1976</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">938175</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2021243</PMID>
        <DateCreated>
            <Year>1991</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1991</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-9645</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>52</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1991</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of veterinary research</Title>
                <ISOAbbreviation>Am. J. Vet. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Toxicity of pyrrolizidine alkaloids from Riddell groundsel (Senecio riddellii) to cattle.</ArticleTitle>
            <Pagination>
                <MedlinePgn>146-51</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The toxicity of Riddell groundsel (Senecio riddellii) gavaged to calves at a known lethal rate was compared with the toxicity of riddelliine and riddelliine N-oxide, the pyrrolizidine alkaloids isolated from the plant, which were fed by intraruminal infusion. Doses of the alkaloids were adjusted to the amount determined to be in the plant and fed individually and in combination. The relative toxicosis in the calves was measured by clinical signs, serum enzyme changes, survival time to morbidity, and histologic changes. Calves fed Senecio riddellii by gavage for 20 consecutive days to provide 45 mg of total pyrrolizidine alkaloids/kg of body weight/d developed clinical signs and serum enzyme changes typical of seneciosis, with 100% morbidity. However, calves receiving riddelliine at 4.5 mg/kg/d for 20 days had neither serum enzyme changes nor clinical signs of pyrrolizidine alkaloidosis. Calves treated with riddelliine N-oxide (40.5 mg/kg/d), and with riddelliine (4.5 mg/kg/d) and riddelliine N-oxide (40.5 mg/kg/d) in combination, had 100% morbidity, although the latter group had fewer liver lesions. These results establish that the N-oxide form of the alkaloid alone is capable of inducing typical Senecio toxicosis in cattle and that the free base level of the plant cannot be considered to be the sole factor in assessing the toxicity of S riddellii.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Molyneux</LastName>
                    <ForeName>R J</ForeName>
                    <Initials>RJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Western Regional Research Center, USDA, Albany, CA 94710.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johnson</LastName>
                    <ForeName>A E</ForeName>
                    <Initials>AE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olsen</LastName>
                    <ForeName>J D</ForeName>
                    <Initials>JD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baker</LastName>
                    <ForeName>D C</ForeName>
                    <Initials>DC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Vet Res</MedlineTA>
            <NlmUniqueID>0375011</NlmUniqueID>
            <ISSNLinking>0002-9645</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011763">Pyrrolizidine Alkaloids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>23246-96-0</RegistryNumber>
                <NameOfSubstance UI="C013672">riddelliine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75056-11-0</RegistryNumber>
                <NameOfSubstance UI="C068583">riddelliine N-oxide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002417">Cattle</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002418">Cattle Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007441">Intubation, Gastrointestinal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000662">veterinary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010939">Plant Poisoning</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000662">veterinary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D010947">Plants, Toxic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011763">Pyrrolizidine Alkaloids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D012674">Senecio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015430">Weight Gain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015431">Weight Loss</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1991</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1991</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1991</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2021243</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18796534</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>01</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1531-2267</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>35</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Nov</Month>
                        <Day>12</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Physiological genomics</Title>
                <ISOAbbreviation>Physiol. Genomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dynamic changes of the renin-angiotensin and associated systems in the rat after pharmacological and dietary interventions in vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn>330-40</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1152/physiolgenomics.00187.2007</ELocationID>
            <Abstract>
                <AbstractText>To address the multiplicity of the renin-angiotensin system (RAS) with particular interest in its local, synergistic regulation, we investigate dynamic changes of the RAS and associated systems in response to external stimuli in the rat. We tested influences of the RAS blockade (candesartan and enalapril), diuretics (hydrochlorothiazide), high lipid diet, and salt loading on tissue mRNA level of 12 principal genes. Under the hemodynamic conditions appropriately predetermined, we quantitatively evaluated mRNA level changes with and without each intervention in five organs-the brain, heart, kidney, liver, and adipose tissues-of male rats (n = 5 each). A total of 250 tissues were examined by real-time PCR. Significant changes in mRNA level (P &lt; 0.05) were found in a drug-, diet- and tissue-specific manner. For instance, 29% of genes (14 out of 48 tissues showing detectable mRNA levels) were differentially regulated by candesartan and enalapril, although both drugs reduced blood pressure to similar extents. When the overall interactions among 12 genes were compared between interventions, the RAS and associated systems appeared to change in the opposite direction between candesartan and high lipid diet in the adipose tissue and between candesartan and salt loading in the heart. Enalapril, however, induced unique patterns of perturbation in the local RAS under the corresponding conditions. Thus, this study provides a fundamental picture of gene expression profile in vivo in the RAS and associated systems. In particular, our data highlight differential regulation between candesartan and enalapril, which may reflect the individual pharmacological properties regarding clinical implications.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ochiai</LastName>
                    <ForeName>Yoshinori</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gene Diagnostics and Therapeutics, Research Institute, International Medical Center of Japan, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Yi-Qiang</ForeName>
                    <Initials>YQ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serizawa</LastName>
                    <ForeName>Masakuni</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kato</LastName>
                    <ForeName>Norihiro</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>09</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Physiol Genomics</MedlineTA>
            <NlmUniqueID>9815683</NlmUniqueID>
            <ISSNLinking>1094-8341</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004041">Dietary Fats</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004232">Diuretics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017673">Sodium Chloride, Dietary</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0J48LPH2TH</RegistryNumber>
                <NameOfSubstance UI="D006852">Hydrochlorothiazide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>69PN84IO1A</RegistryNumber>
                <NameOfSubstance UI="D004656">Enalapril</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S8Q36MD2XX</RegistryNumber>
                <NameOfSubstance UI="C081643">candesartan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001562">Benzimidazoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004041">Dietary Fats</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004232">Diuretics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004656">Enalapril</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006852">Hydrochlorothiazide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011918">Rats, Inbred SHR</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012084">Renin-Angiotensin System</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017673">Sodium Chloride, Dietary</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013777">Tetrazoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">00187.2007</ArticleId>
            <ArticleId IdType="doi">10.1152/physiolgenomics.00187.2007</ArticleId>
            <ArticleId IdType="pubmed">18796534</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10638597</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-9270</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>95</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of gastroenterology</Title>
                <ISOAbbreviation>Am. J. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tamoxifen-induced transient multifocal hepatic fatty infiltration.</ArticleTitle>
            <Pagination>
                <MedlinePgn>277-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Tamoxifen is one of the most commonly used anticancer medications. Hepatic damage secondary to tamoxifen treatment is rare. Tamoxifen-induced multifocal hepatic fatty infiltration has not been reported previously. This report describes one case of steatohepatitis caused by tamoxifen in an elderly woman with a history of breast cancer. The patient had multifocal hepatic fatty infiltration secondary to tamoxifen therapy. After tamoxifen was discontinued, the features of multifocal hepatic fatty infiltration on CT improved dramatically, and hepatic transaminases normalized.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cai</LastName>
                    <ForeName>Q</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Internal Medicine, Marshfield Clinic, Wisconsin, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bensen</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greene</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kirchner</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Gastroenterol</MedlineTA>
            <NlmUniqueID>0421030</NlmUniqueID>
            <ISSNLinking>0002-9270</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>094ZI81Y45</RegistryNumber>
                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018931">Antineoplastic Agents, Hormonal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005234">Fatty Liver</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013629">Tamoxifen</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014057">Tomography, X-Ray Computed</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>1</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>1</Month>
                <Day>19</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>1</Month>
                <Day>19</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10638597</ArticleId>
            <ArticleId IdType="pii">S0002-9270(99)00767-4</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1572-0241.2000.01708.x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15787309</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>05</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-9683</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>98</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Archives des maladies du coeur et des vaisseaux</Title>
                <ISOAbbreviation>Arch Mal Coeur Vaiss</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Torsades de pointes caused by cetirizine overdose].</ArticleTitle>
            <Pagination>
                <MedlinePgn>157-61</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Several therapeutic substances can cause torsades de pointes, especially if they prolong the QT interval and/or if there is an associated hypokalaemia. Certain second generation H1 antihistamines have been incriminated in the occurrence of such ventricular arrhythmias, such as terfenadine and astezimole, which have been withdrawn. Cetirizine, widely used in the treatment of allergic reactions, is a second generation H1 antihistamine with as yet no precautions of use regarding rhythm disturbances. No documented case of arrhythmia attributable to this drug has been reported. We report the case of a dialysed patient with chronic renal failure who had symptomatic episodes of torsades de pointes in the context of hypokalaemia and cetirizine overdose. In the light of this observation it would appear that the prescription of cetirizine is contra-indicated under such conditions.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Renard</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Département de Pathologies Cardiovasculaires, Centre Hospitalier Général de Martigues. renardsebastien@9online.fr</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ostorero</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yvorra</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zerrouk</LastName>
                    <ForeName>Z</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bargas</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bertocchio</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pracchia</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ebagosti</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Torsades de pointes induites par surdosage en cétirizine: à propos d'un cas.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Arch Mal Coeur Vaiss</MedlineTA>
            <NlmUniqueID>0406011</NlmUniqueID>
            <ISSNLinking>0003-9683</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D039563">Histamine H1 Antagonists, Non-Sedating</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YO7261ME24</RegistryNumber>
                <NameOfSubstance UI="D017332">Cetirizine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017332">Cetirizine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D062787">Drug Overdose</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D039563">Histamine H1 Antagonists, Non-Sedating</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012651">Self Medication</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016171">Torsades de Pointes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>25</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>25</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15787309</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20833591</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>09</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>10</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1474-4465</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Lancet. Neurology</Title>
                <ISOAbbreviation>Lancet Neurol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>959-68</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(10)70198-8</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The antiplatelet drug cilostazol is efficacious for prevention of stroke recurrence compared with placebo. We designed the second Cilostazol Stroke Prevention Study (CSPS 2) to establish non-inferiority of cilostazol versus aspirin for prevention of stroke, and to compare the efficacy and safety of cilostazol and aspirin in patients with non-cardioembolic ischaemic stroke.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients aged 20-79 years who had had a cerebral infarction within the previous 26 weeks were enrolled at 278 sites in Japan and allocated to receive 100 mg cilostazol twice daily or 81 mg aspirin once daily for 1-5 years. Patients were allocated according to a computer-generated randomisation sequence by means of a dynamic balancing method using patient information obtained at registration. All patients, study personnel, investigators, and the sponsor were masked to treatment allocation. The primary endpoint was the first occurrence of stroke (cerebral infarction, cerebral haemorrhage, or subarachnoid haemorrhage). The predefined margin of non-inferiority was an upper 95% CI limit for the hazard ratio of 1·33. Analyses were by full-analysis set. This trial is registered with ClinicalTrials.gov, number NCT00234065.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between December, 2003, and October, 2006, 2757 patients were enrolled and randomly allocated to receive cilostazol (n=1379) or aspirin (n=1378), of whom 1337 on cilostazol and 1335 on aspirin were included in analyses; mean follow-up was 29 months (SD 16). The primary endpoint occurred at yearly rates of 2·76% (n=82) in the cilostazol group and 3·71% (n=119) in the aspirin group (hazard ratio 0·743, 95% CI 0·564-0·981; p=0·0357). Haemorrhagic events (cerebral haemorrhage, subarachnoid haemorrhage, or haemorrhage requiring hospital admission) occurred in fewer patients on cilostazol (0·77%, n=23) than on aspirin (1·78%, n=57; 0·458, 0·296-0·711; p=0·0004), but headache, diarrhoea, palpitation, dizziness, and tachycardia were more frequent in the cilostazol group than in the aspirin group.</AbstractText>
                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Cilostazol seems to be non-inferior, and might be superior, to aspirin for prevention of stroke after an ischaemic stroke, and was associated with fewer haemorrhagic events. Therefore, cilostazol could be used for prevention of stroke in patients with non-cardioembolic stroke.</AbstractText>
                <AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Otsuka Pharmaceutical.</AbstractText>
                <CopyrightInformation>Copyright © 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shinohara</LastName>
                    <ForeName>Yukito</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital, Tachikawa, Tokyo, Japan. yshinoha@tachikawa-hosp.gr.jp</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Katayama</LastName>
                    <ForeName>Yasuo</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uchiyama</LastName>
                    <ForeName>Shinichiro</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamaguchi</LastName>
                    <ForeName>Takenori</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Handa</LastName>
                    <ForeName>Shunnosuke</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuoka</LastName>
                    <ForeName>Kempei</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohashi</LastName>
                    <ForeName>Yasuo</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanahashi</LastName>
                    <ForeName>Norio</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamamoto</LastName>
                    <ForeName>Hiroko</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Genka</LastName>
                    <ForeName>Chokoh</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitagawa</LastName>
                    <ForeName>Yasuhisa</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kusuoka</LastName>
                    <ForeName>Hideo</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishimaru</LastName>
                    <ForeName>Katsuya</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsushima</LastName>
                    <ForeName>Motoo</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koretsune</LastName>
                    <ForeName>Yukihiro</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sawada</LastName>
                    <ForeName>Tohru</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamada</LastName>
                    <ForeName>Chikuma</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>CSPS 2 group</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>09</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Lancet Neurol</MedlineTA>
            <NlmUniqueID>101139309</NlmUniqueID>
            <ISSNLinking>1474-4422</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N7Z035406B</RegistryNumber>
                <NameOfSubstance UI="C045645">cilostazol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R16CO5Y76E</RegistryNumber>
                <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Lancet Neurol. 2010 Oct;9(10):942-3</RefSource>
                <PMID Version="1">20833590</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001241">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002544">Cerebral Infarction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055502">Secondary Prevention</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020521">Stroke</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013777">Tetrazoles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Katayama</LastName>
                <ForeName>Yasuo</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Uchiyama</LastName>
                <ForeName>Shinichiro</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamaguchi</LastName>
                <ForeName>Takenori</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Handa</LastName>
                <ForeName>Shunnosuke</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Matsuoka</LastName>
                <ForeName>Kempei</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ohashi</LastName>
                <ForeName>Yasuo</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tanahashi</LastName>
                <ForeName>Norio</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamamoto</LastName>
                <ForeName>Hiroko</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kitagawa</LastName>
                <ForeName>Yasuhisa</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nishimaru</LastName>
                <ForeName>Katsuya</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Genka</LastName>
                <ForeName>Chokoh</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kusuoka</LastName>
                <ForeName>Hideo</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tsushima</LastName>
                <ForeName>Motoo</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Genka</LastName>
                <ForeName>Chokoh</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Koretsune</LastName>
                <ForeName>Yukihiro</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sawada</LastName>
                <ForeName>Tohru</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hamada</LastName>
                <ForeName>Chikuma</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abe</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abe</LastName>
                <ForeName>Koji</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abiko</LastName>
                <ForeName>Seisho</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aiba</LastName>
                <ForeName>Ikuko</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aihara</LastName>
                <ForeName>Hideo</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Akiyama</LastName>
                <ForeName>Hisanao</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Amari</LastName>
                <ForeName>Masakuni</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aoki</LastName>
                <ForeName>Atsushi</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aoki</LastName>
                <ForeName>Nobuo</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aoki</LastName>
                <ForeName>Shinichiro</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aoki</LastName>
                <ForeName>Takeshi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Arai</LastName>
                <ForeName>Koichi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Araki</LastName>
                <ForeName>Takehisa</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Arimura</LastName>
                <ForeName>Hitoshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Arisawa</LastName>
                <ForeName>Masahiko</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Asakura</LastName>
                <ForeName>Kenichi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Asano</LastName>
                <ForeName>Kenichiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Asano</LastName>
                <ForeName>Taku</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Asari</LastName>
                <ForeName>Jun</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Azuma</LastName>
                <ForeName>Tsutomu</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Baba</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bokura</LastName>
                <ForeName>Hirokazu</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Endou</LastName>
                <ForeName>Kazuhiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fujii</LastName>
                <ForeName>Kenichiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fujimori</LastName>
                <ForeName>Kiyoshi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fujimoto</LastName>
                <ForeName>Shunichiro</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fujimoto</LastName>
                <ForeName>Tsukasa</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fujisawa</LastName>
                <ForeName>Hirosuke</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fujita</LastName>
                <ForeName>Nobuya</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fujiwara</LastName>
                <ForeName>Kiyoshi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fukuda</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fukuda</LastName>
                <ForeName>Kenji</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fukuda</LastName>
                <ForeName>Yasuki</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fukunaga</LastName>
                <ForeName>Ryuzo</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fukusako</LastName>
                <ForeName>Toshihiro</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Funauchi</LastName>
                <ForeName>Masahiro</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gi</LastName>
                <ForeName>Hidefuku</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goto</LastName>
                <ForeName>Yasunobu</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hamada</LastName>
                <ForeName>Junichi</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hamada</LastName>
                <ForeName>Rikuzo</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hara</LastName>
                <ForeName>Hitoshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Harada</LastName>
                <ForeName>Kiyoshi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hashikawa</LastName>
                <ForeName>Kazuo</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hatanaka</LastName>
                <ForeName>Mitsuaki</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hattori</LastName>
                <ForeName>Takamichi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hazama</LastName>
                <ForeName>Takanori</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Higashi</LastName>
                <ForeName>Soutarou</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hiramoto</LastName>
                <ForeName>Jun</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hirata</LastName>
                <ForeName>Ikuo</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hirata</LastName>
                <ForeName>Koichi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hirayama</LastName>
                <ForeName>Mikio</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hirayama</LastName>
                <ForeName>Toshikazu</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hirose</LastName>
                <ForeName>Ryuichi</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hisanaga</LastName>
                <ForeName>Kinya</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hodotsuka</LastName>
                <ForeName>Akira</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hohnoki</LastName>
                <ForeName>Shuji</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hoshi</LastName>
                <ForeName>Akihiko</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hoshikawa</LastName>
                <ForeName>Yoshihiro</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hosomi</LastName>
                <ForeName>Naohisa</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Houkin</LastName>
                <ForeName>Kiyohiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Houri</LastName>
                <ForeName>Takashi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ibayashi</LastName>
                <ForeName>Setsuro</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ibayashi</LastName>
                <ForeName>Yukihiro</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ichihara</LastName>
                <ForeName>Kaoru</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ichikawa</LastName>
                <ForeName>Takehiko</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ikeda</LastName>
                <ForeName>Kiyonobu</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ikuta</LastName>
                <ForeName>Naomi</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Imai</LastName>
                <ForeName>Shu</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Imai</LastName>
                <ForeName>Yasuharu</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Imaizumi</LastName>
                <ForeName>Shigeki</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Imamura</LastName>
                <ForeName>Kazuhiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Inoue</LastName>
                <ForeName>Isao</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Irie</LastName>
                <ForeName>Katsumi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Irie</LastName>
                <ForeName>Shinsuke</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ishibashi</LastName>
                <ForeName>Yasuhiro</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ishida</LastName>
                <ForeName>Yoshinori</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ishikawa</LastName>
                <ForeName>Tatsuya</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ishitsuka</LastName>
                <ForeName>Takao</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ito</LastName>
                <ForeName>Masanori</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ito</LastName>
                <ForeName>Yasuhiro</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ito</LastName>
                <ForeName>Yasushi</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Itoh</LastName>
                <ForeName>Jun</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Iwama</LastName>
                <ForeName>Toru</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Iwamura</LastName>
                <ForeName>Makoto</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Iwata</LastName>
                <ForeName>Makoto</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Izumi</LastName>
                <ForeName>Naoto</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kaidou</LastName>
                <ForeName>Misako</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kametsu</LastName>
                <ForeName>Yutaka</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kaminogo</LastName>
                <ForeName>Makio</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kamitsukasa</LastName>
                <ForeName>Ikuo</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kanda</LastName>
                <ForeName>Masutarou</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kaneko</LastName>
                <ForeName>Yoichi</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kashihara</LastName>
                <ForeName>Kenichi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kashiwado</LastName>
                <ForeName>Koichi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kato</LastName>
                <ForeName>Takaaki</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kato</LastName>
                <ForeName>Yasushi</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Katsuta</LastName>
                <ForeName>Toshiro</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kawabe</LastName>
                <ForeName>Yojiro</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kawada</LastName>
                <ForeName>Norikazu</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kawakami</LastName>
                <ForeName>Masahisa</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kawano</LastName>
                <ForeName>Hirokazu</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kayama</LastName>
                <ForeName>Takamasa</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kikuchi</LastName>
                <ForeName>Kensuke</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kimura</LastName>
                <ForeName>Kazumi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kimura</LastName>
                <ForeName>Takashi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kimura</LastName>
                <ForeName>Toru</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kishida</LastName>
                <ForeName>Shuji</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kitagawa</LastName>
                <ForeName>Kazuo</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kitazono</LastName>
                <ForeName>Takanari</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kiya</LastName>
                <ForeName>Katsuzo</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kamiya</LastName>
                <ForeName>Ken</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kodera</LastName>
                <ForeName>Minoru</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Koga</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kohriyama</LastName>
                <ForeName>Tatsuo</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Koike</LastName>
                <ForeName>Tetsuo</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Koizumi</LastName>
                <ForeName>Hiroyasu</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Koizumi</LastName>
                <ForeName>Jinichi</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kojima</LastName>
                <ForeName>Shigeyuki</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kojima</LastName>
                <ForeName>Shunichi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kokunai</LastName>
                <ForeName>Takashi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Komaba</LastName>
                <ForeName>Yuichi</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Komatsumoto</LastName>
                <ForeName>Satoru</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kondo</LastName>
                <ForeName>Rei</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kondou</LastName>
                <ForeName>Hiroaki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Konno</LastName>
                <ForeName>Shu</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kouno</LastName>
                <ForeName>Takeshi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kubo</LastName>
                <ForeName>Naohiko</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuchiki</LastName>
                <ForeName>Hideo</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuga</LastName>
                <ForeName>Yoshihiro</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuramitsu</LastName>
                <ForeName>Toru</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuriyama</LastName>
                <ForeName>Masaru</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuroda</LastName>
                <ForeName>Satoshi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuroda</LastName>
                <ForeName>Yasuo</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuroiwa</LastName>
                <ForeName>Toshihiko</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuroiwa</LastName>
                <ForeName>Yoshiyuki</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuwabara</LastName>
                <ForeName>Satoshi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuwabara</LastName>
                <ForeName>Takeo</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuwahara</LastName>
                <ForeName>Kazuhide</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mabuchi</LastName>
                <ForeName>Shiyoji</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maeda</LastName>
                <ForeName>Masaharu</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maeda</LastName>
                <ForeName>Naoyasu</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maeshiro</LastName>
                <ForeName>Tomohide</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manabe</LastName>
                <ForeName>Yasuhiro</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yasuhiro</LastName>
                <ForeName>Kazuo</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maruyama</LastName>
                <ForeName>Junichi</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Masago</LastName>
                <ForeName>Atsuo</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Matsuda</LastName>
                <ForeName>Matsuda</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Matsumoto</LastName>
                <ForeName>Katsuhisa</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Matsumoto</LastName>
                <ForeName>Sadayuki</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Matsumoto</LastName>
                <ForeName>Takashi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Matsumoto</LastName>
                <ForeName>Yuzo</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Matsumura</LastName>
                <ForeName>Kiichiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Matsumura</LastName>
                <ForeName>Naoki</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mihara</LastName>
                <ForeName>Ban</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mikawa</LastName>
                <ForeName>Shigeki</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Minagawa</LastName>
                <ForeName>Makoto</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Minematsu</LastName>
                <ForeName>Kazuo</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mishima</LastName>
                <ForeName>Nobuya</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mitake</LastName>
                <ForeName>Shigehisa</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mitani</LastName>
                <ForeName>Kazuko</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Miyake</LastName>
                <ForeName>Miyake</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Miyake</LastName>
                <ForeName>Shigeru</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Miyashita</LastName>
                <ForeName>Takeshi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Miyata</LastName>
                <ForeName>Shirou</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mizusawa</LastName>
                <ForeName>Hidehiro</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Momoi</LastName>
                <ForeName>Hiroki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mori</LastName>
                <ForeName>Shuichi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morikawa</LastName>
                <ForeName>Atsunori</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moriwaki</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morooka</LastName>
                <ForeName>Yoshito</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Murai</LastName>
                <ForeName>Hiroyuki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Murakami</LastName>
                <ForeName>Kinshiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Murakawa</LastName>
                <ForeName>Takatsugu</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Murao</LastName>
                <ForeName>Kennichi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Murata</LastName>
                <ForeName>Takahiko</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mutou</LastName>
                <ForeName>Tatsurou</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nabatame</LastName>
                <ForeName>Hidehiko</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nagahori</LastName>
                <ForeName>Takeshi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nagao</LastName>
                <ForeName>Takeki</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nagata</LastName>
                <ForeName>Ken</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nagayama</LastName>
                <ForeName>Tooru</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Naito</LastName>
                <ForeName>Yutaka</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakagaki</LastName>
                <ForeName>Hiroyuki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakagawa</LastName>
                <ForeName>Shin-ichi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakagawara</LastName>
                <ForeName>Jyoji</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakahara</LastName>
                <ForeName>Toshinori</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakajima</LastName>
                <ForeName>Makoto</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakajima</LastName>
                <ForeName>Shin</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakane</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakano</LastName>
                <ForeName>Imaharu</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakano</LastName>
                <ForeName>Satoshi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nakao</LastName>
                <ForeName>Satoshi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Namba</LastName>
                <ForeName>Hiroki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Narikawa</LastName>
                <ForeName>Kouichi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Naritomi</LastName>
                <ForeName>Hiroaki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Naruse</LastName>
                <ForeName>Satoshi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nemoto</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Niikawa</LastName>
                <ForeName>Shuji</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nishida</LastName>
                <ForeName>Yasuto</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nishikawa</LastName>
                <ForeName>Masakatsu</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nishino</LastName>
                <ForeName>Shigeki</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nishiura</LastName>
                <ForeName>Tsukasa</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nishizawa</LastName>
                <ForeName>Masatoyo</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nitta</LastName>
                <ForeName>Hisashi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Niwa</LastName>
                <ForeName>Jun</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nomura</LastName>
                <ForeName>Tatsufumi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nonoguchi</LastName>
                <ForeName>Naosuke</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ochi</LastName>
                <ForeName>Hirofumi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ochiai</LastName>
                <ForeName>Junn</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Oda</LastName>
                <ForeName>Kenichiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ohnishi</LastName>
                <ForeName>Takanori</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ohno</LastName>
                <ForeName>Tsukasa</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ohtaki</LastName>
                <ForeName>Masafumi</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ohtani</LastName>
                <ForeName>Yoichi</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ohyama</LastName>
                <ForeName>Hideki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Okada</LastName>
                <ForeName>Hitoshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Okada</LastName>
                <ForeName>Kazunori</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Okada</LastName>
                <ForeName>Takaharu</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Okamoto</LastName>
                <ForeName>Koichi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Okamura</LastName>
                <ForeName>Hideki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Oku</LastName>
                <ForeName>Takamitsu</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Okubo</LastName>
                <ForeName>Seiji</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Okuda</LastName>
                <ForeName>Bungo</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Okuda</LastName>
                <ForeName>Satoshi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ono</LastName>
                <ForeName>Junichi</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ono</LastName>
                <ForeName>Seiichi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Onuma</LastName>
                <ForeName>Ayumu</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Oono</LastName>
                <ForeName>Kunimasa</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ootomo</LastName>
                <ForeName>Manabu</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Orimo</LastName>
                <ForeName>Satoshi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Osawa</LastName>
                <ForeName>Mikio</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Oshio</LastName>
                <ForeName>Kotaro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Riku</LastName>
                <ForeName>Shigeo</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Saito</LastName>
                <ForeName>Hitoshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Saitou</LastName>
                <ForeName>Hisatoshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sakae</LastName>
                <ForeName>Nobutaka</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sakai</LastName>
                <ForeName>Kennichi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sakai</LastName>
                <ForeName>Nobuyuki</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sakakibara</LastName>
                <ForeName>Toshimasa</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sako</LastName>
                <ForeName>Kazuhiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sasaki</LastName>
                <ForeName>Takahiro</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sato</LastName>
                <ForeName>Nobuyuki</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sato</LastName>
                <ForeName>Tatsuya</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sato</LastName>
                <ForeName>Yoshitomo</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sawa</LastName>
                <ForeName>Hideki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seike</LastName>
                <ForeName>Masato</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seto</LastName>
                <ForeName>Makiko</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shibata</LastName>
                <ForeName>Kazunori</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shigeno</LastName>
                <ForeName>Koji</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shii</LastName>
                <ForeName>Hirofumi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shimada</LastName>
                <ForeName>Takao</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shimizu</LastName>
                <ForeName>Keiji</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shimizu</LastName>
                <ForeName>Kennji</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shimizu</LastName>
                <ForeName>Kotoyuki</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shimizu</LastName>
                <ForeName>Tadakazu</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shimizu</LastName>
                <ForeName>Takako</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shimizu</LastName>
                <ForeName>Takao</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shimizu</LastName>
                <ForeName>Takashi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shimosaka</LastName>
                <ForeName>Shinichi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shinbou</LastName>
                <ForeName>Tomoyuki</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shinonaga</LastName>
                <ForeName>Masamichi</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sogabe</LastName>
                <ForeName>Takashi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suda</LastName>
                <ForeName>Sumio</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sugihara</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sunada</LastName>
                <ForeName>Yoshihide</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suzuki</LastName>
                <ForeName>Akifumi</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suzuki</LastName>
                <ForeName>Mikio</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suzuki</LastName>
                <ForeName>Norihiro</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suzuki</LastName>
                <ForeName>Nozomi</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suzuki</LastName>
                <ForeName>Susumu</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suzuki</LastName>
                <ForeName>Takayo</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suzuki</LastName>
                <ForeName>Yasutaka</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suzuki</LastName>
                <ForeName>Yutaka</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tabe</LastName>
                <ForeName>Hiroyuki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tagaya</LastName>
                <ForeName>Masafumi</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taguchi</LastName>
                <ForeName>Haruyoshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takaba</LastName>
                <ForeName>Hitonori</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takagi</LastName>
                <ForeName>Makoto</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takagi</LastName>
                <ForeName>Shigeharu</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takahashi</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takahashi</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takamatsu</LastName>
                <ForeName>Kazuhiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takasago</LastName>
                <ForeName>Teiichi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takasato</LastName>
                <ForeName>Yoshio</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takata</LastName>
                <ForeName>Hisashi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takaya</LastName>
                <ForeName>Satoru</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takeda</LastName>
                <ForeName>Hidetaka</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takenaka</LastName>
                <ForeName>Katsunobu</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takeuchi</LastName>
                <ForeName>Shigekazu</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takimoto</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Takizawa</LastName>
                <ForeName>Katsumi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tamaki</LastName>
                <ForeName>Mitsuyuki</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tanabe</LastName>
                <ForeName>Hideki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tanaka</LastName>
                <ForeName>Ryuichi</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tatsukawa</LastName>
                <ForeName>Masafumi</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Terada</LastName>
                <ForeName>Yukitoshi</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Teramoto</LastName>
                <ForeName>Jun</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Terasaka</LastName>
                <ForeName>Shunsuke</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Toba</LastName>
                <ForeName>Yasuyuki</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tokuda</LastName>
                <ForeName>Takahiko</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tokunaga</LastName>
                <ForeName>Yoshiharu</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tokuoka</LastName>
                <ForeName>Kentaro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tokuriki</LastName>
                <ForeName>Yasuhiko</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Touma</LastName>
                <ForeName>Yasuo</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Toyooka</LastName>
                <ForeName>Shiho</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tsuji</LastName>
                <ForeName>Tetsurou</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ueda</LastName>
                <ForeName>Hirokazu</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Uenohara</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Uno</LastName>
                <ForeName>Eiichi</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Uno</LastName>
                <ForeName>Masaaki</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Uozumi</LastName>
                <ForeName>Takenori</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Urui</LastName>
                <ForeName>Seishiro</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ushikoshi</LastName>
                <ForeName>Satoshi</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Utsumi</LastName>
                <ForeName>Hiroya</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wada</LastName>
                <ForeName>Hirochiyo</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wakata</LastName>
                <ForeName>Nobuo</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wakayama</LastName>
                <ForeName>Akatsuki</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wakayama</LastName>
                <ForeName>Yoshihiro</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Waki</LastName>
                <ForeName>Riichiro</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wanifuchi</LastName>
                <ForeName>Hiroshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Watanabe</LastName>
                <ForeName>Hiroyuki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Watanabe</LastName>
                <ForeName>Kazuyoshi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Watanabe</LastName>
                <ForeName>Yukio</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yagi</LastName>
                <ForeName>Hideo</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yagi</LastName>
                <ForeName>Kennji</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yakushiji</LastName>
                <ForeName>Yusuke</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamada</LastName>
                <ForeName>Takeshi</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamagata</LastName>
                <ForeName>Hajime</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamagata</LastName>
                <ForeName>Sen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamaguchi</LastName>
                <ForeName>Hideshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamaguchi</LastName>
                <ForeName>Shuuhei</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamakawa</LastName>
                <ForeName>Yuzo</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamamoto</LastName>
                <ForeName>Masahiro</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamamoto</LastName>
                <ForeName>Teiji</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamamoto</LastName>
                <ForeName>Toru</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamana</LastName>
                <ForeName>Tomoko</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamane</LastName>
                <ForeName>Kanji</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamane</LastName>
                <ForeName>Kiyomi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamasaki</LastName>
                <ForeName>Kenji</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamasaki</LastName>
                <ForeName>Masahiro</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamashita</LastName>
                <ForeName>Katsuhiro</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamawaki</LastName>
                <ForeName>Takemori</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yamazaki</LastName>
                <ForeName>Motoyoshi</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yanagisawa</LastName>
                <ForeName>Toshiharu</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yano</LastName>
                <ForeName>Kou</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yasaka</LastName>
                <ForeName>Masahiro</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yasuda</LastName>
                <ForeName>Hitoshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yasui</LastName>
                <ForeName>Akihiro</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yazaki</LastName>
                <ForeName>Masahide</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yokochi</LastName>
                <ForeName>Masayuki</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yokoyama</LastName>
                <ForeName>Hiroaki</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yoshii</LastName>
                <ForeName>Jin</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yoshikawa</LastName>
                <ForeName>Hiroo</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yoshimura</LastName>
                <ForeName>Hitoshi</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yoshioka</LastName>
                <ForeName>Akira</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yoshizawa</LastName>
                <ForeName>Toshihiro</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yuki</LastName>
                <ForeName>Kiyoshi</ForeName>
                <Initials>K</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>9</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1474-4422(10)70198-8</ArticleId>
            <ArticleId IdType="doi">10.1016/S1474-4422(10)70198-8</ArticleId>
            <ArticleId IdType="pubmed">20833591</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20098333</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-3678</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>32</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of pediatric hematology/oncology</Title>
                <ISOAbbreviation>J. Pediatr. Hematol. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction.</ArticleTitle>
            <Pagination>
                <MedlinePgn>134-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MPH.0b013e3181c95a0c</ELocationID>
            <Abstract>
                <AbstractText>Cardiac disease is a significant complication of childhood oncologic therapy. We report the case of a 14-year-old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA). Despite cessation of daunomycin, she demonstrated fluctuating systolic function in relation to ATRA administration. Improvement and deterioration in systolic function on echocardiogram and serum B-natriuretic peptide levels were seen while receiving ATRA 1 week on and 1 week off, respectively, during the maintenance phase of therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mahadeo</LastName>
                    <ForeName>Kris Michael</ForeName>
                    <Initials>KM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Hematology-Oncology, Children's Hospital at Montefiore, Bronx, NY, USA. KRISMD03@hotmail.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dhall</LastName>
                    <ForeName>Girish</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ettinger</LastName>
                    <ForeName>Lawrence J</ForeName>
                    <Initials>LJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kurer</LastName>
                    <ForeName>Cheryl C</ForeName>
                    <Initials>CC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Pediatr Hematol Oncol</MedlineTA>
            <NlmUniqueID>9505928</NlmUniqueID>
            <ISSNLinking>1077-4114</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>114471-18-0</RegistryNumber>
                <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5688UTC01R</RegistryNumber>
                <NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>ZS7284E0ZP</RegistryNumber>
                <NameOfSubstance UI="D003630">Daunorubicin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000903">Antibiotics, Antineoplastic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009202">Cardiomyopathies</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003630">Daunorubicin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015473">Leukemia, Promyelocytic, Acute</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020097">Natriuretic Peptide, Brain</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014212">Tretinoin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPH.0b013e3181c95a0c</ArticleId>
            <ArticleId IdType="pubmed">20098333</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17459480</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1549-4713</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>114</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Ophthalmology</Title>
                <ISOAbbreviation>Ophthalmology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2244-51</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the effect of bimatoprost and the fixed combination of latanoprost and timolol (LTFC) on 24-hour mean intraocular pressure (IOP) after patients are switched from a nonfixed combination of latanoprost and timolol.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Randomized, double-masked, multicenter clinical trial.</AbstractText>
                <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Two hundred patients with glaucoma or ocular hypertension.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Included were patients who were controlled (IOP &lt; 21 mmHg) on the nonfixed combination of latanoprost and timolol for at least 3 months before the baseline visit or patients on monotherapy with either latanoprost or timolol who were eligible for dual therapy not being fully controlled on monotherapy. The latter group of patients underwent a 6-week wash-in phase with the nonfixed combination of latanoprost and timolol before baseline IOP determination and study inclusion. Supine and sitting position IOPs were recorded at 8 pm, midnight, 5 am, 8 am, noon, and 4 pm at baseline, week 6, and week 12 visits.</AbstractText>
                <AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">An analysis of covariance model was used for a noninferiority test of the primary efficacy variable, with mean area under the 24-hour IOP curve after 12 weeks of treatment as response variable and treatment, center, and baseline IOP as factors. A secondary analysis was performed on the within-treatment change from baseline.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean baseline IOPs were 16.3+/-3.3 mmHg and 15.5+/-2.9.mmHg in the bimatoprost and LTFC groups, respectively. At week 12, mean IOPs were 16.1+/-2.5 mmHg for the bimatoprost group and 16.3+/-3.7 mmHg for the LTFC group, and no significant difference between the 2 treatment groups could be found. As compared with baseline, mean IOP increased by 0.3+/-3.6 mmHg during the day and decreased by 0.8+/-3.8 mmHg during the night in the bimatoprost group, whereas there were increases of 1.43+/-2.6 mmHg and 0.14+/-3.2 mmHg in the LTFC group, respectively.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bimatoprost is not inferior to the LTFC in maintaining IOP at a controlled level during a 24-hour period in patients switched from the nonfixed combination of latanoprost and timolol.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rossetti</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinica Oculistica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Ospedale San Paolo, Milan, Italy. lucamrossetti@libero.it</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karabatsas</LastName>
                    <ForeName>Costas H</ForeName>
                    <Initials>CH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Topouzis</LastName>
                    <ForeName>Fotis</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vetrugno</LastName>
                    <ForeName>Michele</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Centofanti</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boehm</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Viswanathan</LastName>
                    <ForeName>Ananth</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vorwerk</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goldblum</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>04</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ophthalmology</MedlineTA>
            <NlmUniqueID>7802443</NlmUniqueID>
            <ISSNLinking>0161-6420</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000577">Amides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011461">Prostaglandins F, Synthetic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C420823">bimatoprost</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4208238832</RegistryNumber>
                <NameOfSubstance UI="D003008">Cloprostenol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6Z5B6HVF6O</RegistryNumber>
                <NameOfSubstance UI="C072042">latanoprost</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>817W3C6175</RegistryNumber>
                <NameOfSubstance UI="D013999">Timolol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000577">Amides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000959">Antihypertensive Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002940">Circadian Rhythm</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003008">Cloprostenol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005902">Glaucoma, Open-Angle</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007429">Intraocular Pressure</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008055">Lipids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009798">Ocular Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011461">Prostaglandins F, Synthetic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013999">Timolol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014065">Tonometry, Ocular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2007</Year>
                <Month>1</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2007</Year>
                <Month>1</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0161-6420(07)00119-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ophtha.2007.01.025</ArticleId>
            <ArticleId IdType="pubmed">17459480</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1722357</PMID>
        <DateCreated>
            <Year>1992</Year>
            <Month>02</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1992</Year>
            <Month>02</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0300-483X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>70</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1991</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology</Title>
                <ISOAbbreviation>Toxicology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Behavior of alpha 2u-globulin accumulating in kidneys of male rats treated with d-limonene: kidney-type alpha 2u-globulin in the urine as a marker of d-limonene nephropathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>173-83</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Effects of d-limonene on alpha 2u-globulin in the kidneys, urine and serum were examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting analysis. Treatment of male rats with d-limonene by gavage for 14 consecutive days (300 mg/kg/day) caused accumulation of hyaline droplets in renal proximal tubule cells, and a marked intensification of a protein band corresponding to the kidney-type alpha 2u-globulin, with a molecular weight calculated to be approximately 16 kDa. However, no significant changes in the serum alpha 2u-globulin (native-type) band, of approximately 19 kDa, were observed between treated rats and controls, suggesting that circulating alpha 2u-globulin levels were not affected by the d-limonene administration. While the molecular weight of the major alpha 2u-globulin in the urine from control rats was the same as that in the serum (native-type), marked increase in the protein band corresponding to kidney-type-alpha 2u-globulin was observed in the urine from treated rats. The results were indicative of elimination of alpha 2u-globulin from the kidney to urine, the appearance of kidney-type-alpha 2u-globulin in urine implying disruption or exfoliation of proximal tubule cells. Therefore, it is suggested that the presence of the alpha 2u-globulin (kidney-type) in the urine might be used as an indicator of chemically induced alpha 2u-globulin nephropathy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Saito</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Environmental Health Science Laboratory, Sumitomo Chemical Co., Ltd., Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uwagawa</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaneko</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshitake</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>NETHERLANDS</Country>
            <MedlineTA>Toxicology</MedlineTA>
            <NlmUniqueID>0361055</NlmUniqueID>
            <ISSNLinking>0300-483X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000510">Alpha-Globulins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053138">Cyclohexenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013729">Terpenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C013803">alpha 2u globulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9MC3I34447</RegistryNumber>
                <NameOfSubstance UI="C008281">limonene</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000510">Alpha-Globulins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053138">Cyclohexenes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004591">Electrophoresis, Polyacrylamide Gel</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015151">Immunoblotting</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011919">Rats, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013729">Terpenes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1991</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1991</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1991</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1722357</ArticleId>
            <ArticleId IdType="pii">0300-483X(91)90044-2</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11999600</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>05</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>08</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0265-0215</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of anaesthesiology</Title>
                <ISOAbbreviation>Eur J Anaesthesiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Localized abdominal pain following sympathetic blockade with bretylium for the management of complex regional pain syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>147-8</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Molyneux</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Venn</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Dwyer</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Anaesthesiol</MedlineTA>
            <NlmUniqueID>8411711</NlmUniqueID>
            <ISSNLinking>0265-0215</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018674">Adrenergic Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>78ZP3YR353</RegistryNumber>
                <NameOfSubstance UI="D001950">Bretylium Tosylate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015746">Abdominal Pain</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018674">Adrenergic Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001340">Autonomic Nerve Block</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001950">Bretylium Tosylate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004244">Dizziness</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007024">Hypotension, Orthostatic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007866">Leg</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000294">innervation</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012019">Reflex Sympathetic Dystrophy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11999600</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14695728</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>12</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>02</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-3022</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>100</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anesthesiology</Title>
                <ISOAbbreviation>Anesthesiology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sodium bisulfite: scapegoat for chloroprocaine neurotoxicity?</ArticleTitle>
            <Pagination>
                <MedlinePgn>85-91</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neurologic deficits after apparent intrathecal injection of 3% Nesacaine-CE intended for epidural administration created concern about the potential toxicity of chloroprocaine and the preservative sodium bisulfite. Although bisulfite-free formulations of chloroprocaine were subsequently introduced into clinical practice, the relative toxicities of this anesthetic and preservative were never clearly established. The current studies used a relevant functional and histologic model to investigate the intrathecal neurotoxicity of these two compounds.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In the first experiment, rats implanted with intrathecal catheters were given one of two commercially available solutions of chloroprocaine, one of which contained sodium bisulfite; control animals received saline. Animals were assessed for sensory impairment 7 days after administration using the tail-flick test and were killed to obtain histologic specimens to quantify nerve injury. In the second experiment, identical methodology was used to investigate the effects of freshly prepared solutions of chloroprocaine, chloroprocaine with sodium bisulfite, sodium bisulfite, and saline.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The two experiments yielded similar results. In experiment 1, tail-flick latencies and nerve injury scores after administration of plain chloroprocaine were significantly greater than those of chloroprocaine containing bisulfite. Injury scores for animals receiving chloroprocaine with bisulfite were elevated compared with those for animals given saline. In experiment 2, animals receiving plain chloroprocaine developed elevations in tail-flick latencies and nerve injury scores that were significantly greater than those for all other groups. Nerve injury scores with chloroprocaine containing bisulfite were greater than with saline or bisulfite alone. Tail-flick latencies and nerve injury scores with bisulfite alone were similar to those with saline.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical deficits associated with unintentional intrathecal injection of chloroprocaine likely resulted from a direct effect of the anesthetic, not the preservative. The data also suggest that bisulfite can reduce neurotoxic damage induced by intrathecal local anesthetic.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Taniguchi</LastName>
                    <ForeName>Masahiko</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departmentof Anesthesiology and Perioperative Care, University of California, San Francisco, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bollen</LastName>
                    <ForeName>Andrew W</ForeName>
                    <Initials>AW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drasner</LastName>
                    <ForeName>Kenneth</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>GM51887</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Anesthesiology</MedlineTA>
            <NlmUniqueID>1300217</NlmUniqueID>
            <ISSNLinking>0003-3022</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000779">Anesthetics, Local</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013447">Sulfites</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4Z8Y51M438</RegistryNumber>
                <NameOfSubstance UI="D011343">Procaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5YVB0POT2H</RegistryNumber>
                <NameOfSubstance UI="C004616">chloroprocaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7631-90-5</RegistryNumber>
                <NameOfSubstance UI="C009279">sodium bisulfite</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Anesthesiology. 2004 Nov;101(5):1246-7; author reply 1247-8</RefSource>
                <PMID Version="1">15505475</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Anesthesiology. 2004 Nov;101(5):1247; author reply 1247-8</RefSource>
                <PMID Version="1">15505477</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000779">Anesthetics, Local</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007278">Injections, Spinal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020258">Neurotoxicity Syndromes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010147">Pain Measurement</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010525">Peripheral Nerves</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011343">Procaine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011930">Reaction Time</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013447">Sulfites</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>12</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>2</Month>
                <Day>3</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>12</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14695728</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18072176</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1556-9039</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>3</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medical toxicology : official journal of the American College of Medical Toxicology</Title>
                <ISOAbbreviation>J Med Toxicol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Case files of the Drexel University Medical Toxicology Fellowship: methadone-induced QTc prolongation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>190-4</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>Stella C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Emergency Medicine, Division of Medical Toxicology, Drexel University College of Medicine, Philadelphia, PA, USA. scw101@gmail.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roberts</LastName>
                    <ForeName>James R</ForeName>
                    <Initials>JR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Med Toxicol</MedlineTA>
            <NlmUniqueID>101284598</NlmUniqueID>
            <ISSNLinking>1556-9039</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009292">Narcotic Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009294">Narcotics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>36B82AMQ7N</RegistryNumber>
                <NameOfSubstance UI="D009270">Naloxone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>UC6VBE7V1Z</RegistryNumber>
                <NameOfSubstance UI="D008691">Methadone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Sci. 2000 Jul;320(1):9-12</RefSource>
                <PMID Version="1">10910367</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Gen Intern Med. 2006 Nov;21(11):C9-C12</RefSource>
                <PMID Version="1">17026725</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 2002 Sep 17;137(6):501-4</RefSource>
                <PMID Version="1">12230351</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2002 Nov;303(2):688-94</RefSource>
                <PMID Version="1">12388652</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Clin Toxicol. 2002;40(7):867-79</RefSource>
                <PMID Version="1">12507056</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2003 Apr 23-30;289(16):2120-7</RefSource>
                <PMID Version="1">12709470</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pain. 2003 Oct;105(3):499-506</RefSource>
                <PMID Version="1">14527710</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Psychopharmacol. 2004 Aug;24(4):446-8</RefSource>
                <PMID Version="1">15232338</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Intensive Care Med. 2004 Aug;30(8):1690-1</RefSource>
                <PMID Version="1">15185068</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pain Symptom Manage. 2004 Oct;28(4):301-3</RefSource>
                <PMID Version="1">15471646</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Heart J. 1973 Nov;86(5):663-8</RefSource>
                <PMID Version="1">4743335</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Appl Toxicol. 1983 Nov-Dec;3(6):536-42</RefSource>
                <PMID Version="1">6662295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Cardiol. 2005 Apr 1;95(7):915-8</RefSource>
                <PMID Version="1">15781034</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Emerg Med. 2005 Jul;29(1):73-5</RefSource>
                <PMID Version="1">15961013</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Swiss Med Wkly. 2005 May 14;135(19-20):282-5</RefSource>
                <PMID Version="1">15986265</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Crit Care Med. 2006 Jan;7(1):83-5</RefSource>
                <PMID Version="1">16395081</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Cardiol. 2006 Apr 15;97(8):1244-6</RefSource>
                <PMID Version="1">16616034</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Intern Med. 2006 Jun 26;166(12):1280-7</RefSource>
                <PMID Version="1">16801510</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pain Symptom Manage. 2006 Aug;32(2):180-5</RefSource>
                <PMID Version="1">16877186</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2006 Aug 12;368(9535):556-7</RefSource>
                <PMID Version="1">16905001</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Toxicol (Phila). 2006;44(6-7):803-932</RefSource>
                <PMID Version="1">17015284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2001 Oct;299(1):220-6</RefSource>
                <PMID Version="1">11561083</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D062787">Drug Overdose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004632">Emergency Medical Services</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008133">Long QT Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008691">Methadone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009270">Naloxone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009292">Narcotic Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009294">Narcotics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016171">Torsades de Pointes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3550015</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18072176</ArticleId>
            <ArticleId IdType="pmc">PMC3550015</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8541062</PMID>
        <DateCreated>
            <Year>1996</Year>
            <Month>02</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1996</Year>
            <Month>02</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0870-2551</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>14</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>1995</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology</Title>
                <ISOAbbreviation>Rev Port Cardiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Myocardial hypertrophy due to isoproterenol. The preventive action of verapamil].</ArticleTitle>
            <Pagination>
                <MedlinePgn>847-51</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Póvoa</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universidade Federal de São Paulo, Escola Paulista de Medicina, Brasil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manzoli</LastName>
                    <ForeName>M T</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferreira</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murad</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simões</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferreira</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luna</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>por</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Hipertrofia miocárdica pelo isoproterenol. Acção preventiva do verapamil.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>PORTUGAL</Country>
            <MedlineTA>Rev Port Cardiol</MedlineTA>
            <NlmUniqueID>8710716</NlmUniqueID>
            <ISSNLinking>0870-2551</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>CJ0O37KU29</RegistryNumber>
                <NameOfSubstance UI="D014700">Verapamil</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L628TT009W</RegistryNumber>
                <NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006332">Cardiomegaly</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002316">Cardiotonic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004353">Drug Evaluation, Preclinical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007545">Isoproterenol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009206">Myocardium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018709">Statistics, Nonparametric</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014700">Verapamil</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1995</Year>
                <Month>11</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1995</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1995</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8541062</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18072173</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1556-9039</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>3</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medical toxicology : official journal of the American College of Medical Toxicology</Title>
                <ISOAbbreviation>J Med Toxicol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>178-81</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Manini</LastName>
                    <ForeName>Alex F</ForeName>
                    <Initials>AF</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York City Poison Center, New York, NY, USA. manina01@med.nyu.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raspberry</LastName>
                    <ForeName>Dara</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffman</LastName>
                    <ForeName>Robert S</ForeName>
                    <Initials>RS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>Lewis S</ForeName>
                    <Initials>LS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Med Toxicol</MedlineTA>
            <NlmUniqueID>101284598</NlmUniqueID>
            <ISSNLinking>1556-9039</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6UKA5VEJ6X</RegistryNumber>
                <NameOfSubstance UI="C092292">ziprasidone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BF4C9Z1J53</RegistryNumber>
                <NameOfSubstance UI="D000547">Amantadine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WK2XYI10QM</RegistryNumber>
                <NameOfSubstance UI="D007052">Ibuprofen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Psychiatry. 2001 Nov;158(11):1774-82</RefSource>
                <PMID Version="1">11691681</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Rev Neurother. 2006 Aug;6(8):1129-38</RefSource>
                <PMID Version="1">16893341</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Opin Pharmacother. 2001 Oct;2(10):1655-62</RefSource>
                <PMID Version="1">11825308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Ther. 2002 Jan;24(1):21-37</RefSource>
                <PMID Version="1">11833834</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Psychiatry. 2002 Jun;180:515-22</RefSource>
                <PMID Version="1">12042230</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacol Bull. 2001 Autumn;35(4):66-79</RefSource>
                <PMID Version="1">12397857</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMJ. 2002 Nov 9;325(7372):1070</RefSource>
                <PMID Version="1">12424166</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Psychopharmacol. 2004 Feb;24(1):62-9</RefSource>
                <PMID Version="1">14709949</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2004 Mar 4;350(10):1013-22</RefSource>
                <PMID Version="1">14999113</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Intern Med. 2004 Jun 28;164(12):1293-7</RefSource>
                <PMID Version="1">15226162</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Postgrad Med. 2004 Oct;116(4):49-51, 55-9, 63</RefSource>
                <PMID Version="1">15510593</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Coll Cardiol. 1983 Nov;2(5):806-17</RefSource>
                <PMID Version="1">6630761</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med. 1984 Aug;77(2):388-91</RefSource>
                <PMID Version="1">6465184</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Heart J. 1986 Jun;111(6):1088-93</RefSource>
                <PMID Version="1">3716982</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1995 Apr 21;81(2):299-307</RefSource>
                <PMID Version="1">7736582</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Psychiatr Scand. 2005 Mar;111(3):171-6</RefSource>
                <PMID Version="1">15701100</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Psychopharmacol. 2005 Mar;19(2):205-6</RefSource>
                <PMID Version="1">15728441</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Psychiatry. 2005;66 Suppl 6:5-10</RefSource>
                <PMID Version="1">16107178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acad Emerg Med. 2005 Dec;12(12):1167-72</RefSource>
                <PMID Version="1">16282517</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CNS Spectr. 2005 Nov;10(11 Suppl 17):1-20</RefSource>
                <PMID Version="1">16381088</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Psychiatry. 2006 Apr;67(4):509-16</RefSource>
                <PMID Version="1">16669715</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Psychiatry. 2006 Apr;67(4):638-42</RefSource>
                <PMID Version="1">16669729</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychosomatics. 2006 May-Jun;47(3):264-8</RefSource>
                <PMID Version="1">16684946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Geriatr Psychiatry. 2006 Jul;14(7):629-33</RefSource>
                <PMID Version="1">16816018</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Gen Psychiatry. 2001 Dec;58(12):1161-7</RefSource>
                <PMID Version="1">11735845</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000547">Amantadine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018712">Analgesics, Non-Narcotic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D062787">Drug Overdose</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007052">Ibuprofen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008133">Long QT Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013406">Suicide, Attempted</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013844">Thiazoles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016171">Torsades de Pointes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3550025</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18072173</ArticleId>
            <ArticleId IdType="pmc">PMC3550025</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10712995</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>04</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>04</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0012-3692</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>117</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Chest</Title>
                <ISOAbbreviation>Chest</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>708-13</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="STUDY OBJECTIVES" NlmCategory="OBJECTIVE">We previously reported eight patients who developed Churg-Strauss syndrome in association with zafirlukast treatment for asthma and postulated that the syndrome resulted from unmasking of a previously existing condition due to corticosteroid withdrawal and not from a direct drug effect. The availability of montelukast, a new leukotriene receptor antagonist with a different molecular structure, permitted us to test this hypothesis. Our goals were to ascertain whether the Churg-Strauss syndrome developed in patients taking montelukast and other novel asthma medications, and to describe potential mechanisms for the syndrome.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Case series.</AbstractText>
                <AbstractText Label="SETTING" NlmCategory="METHODS">Outpatient and hospital practices of pulmonologists in the United States and Belgium.</AbstractText>
                <AbstractText Label="PATIENTS" NlmCategory="METHODS">Four adults (one man, three women) who received montelukast as treatment for asthma; two women who received salmeterol/fluticasone therapy, but not montelukast.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Churg-Strauss syndrome developed in the four asthmatic patients who received montelukast. In each case, there was a long history of difficult-to-control asthma characterized by multiple exacerbations that had required frequent courses of oral systemic corticosteroids or high doses of inhaled corticosteroids for control. Two other asthmatics who received fluticasone and salmeterol but not montelukast therapy developed the same syndrome with tapering doses of oral or high doses of inhaled corticosteroids.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The occurrence of Churg-Strauss syndrome in asthmatic patients receiving leukotriene modifiers appears to be related to unmasking of an underlying vasculitic syndrome that is initially clinically recognized as moderate to severe asthma and treated with corticosteroids. Montelukast does not appear to directly cause the syndrome in these patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wechsler</LastName>
                    <ForeName>M E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Medicine, Brigham &amp; Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Finn</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gunawardena</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Westlake</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barker</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haranath</LastName>
                    <ForeName>S P</ForeName>
                    <Initials>SP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pauwels</LastName>
                    <ForeName>R A</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kips</LastName>
                    <ForeName>J C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drazen</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Chest</MedlineTA>
            <NlmUniqueID>0231335</NlmUniqueID>
            <ISSNLinking>0012-3692</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018927">Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020024">Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MHM278SD3E</RegistryNumber>
                <NameOfSubstance UI="C093875">montelukast</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Chest. 2001 Feb;119(2):668</RefSource>
                <PMID Version="1">11171764</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Chest. 2000 Nov;118(5):1515-6</RefSource>
                <PMID Version="1">11083717</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Chest. 2001 Dec;120(6):2116</RefSource>
                <PMID Version="1">11742954</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Chest. 2000 Oct;118(4):1228-9</RefSource>
                <PMID Version="1">11035708</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000085">Acetates</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000305">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018927">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001249">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015267">Churg-Strauss Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020024">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011804">Quinolines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>3</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>3</Month>
                <Day>14</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>3</Month>
                <Day>14</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10712995</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17557908</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>08</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>10</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1096-6080</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>99</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicological sciences : an official journal of the Society of Toxicology</Title>
                <ISOAbbreviation>Toxicol. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mouse liver effects of cyproconazole, a triazole fungicide: role of the constitutive androstane receptor.</ArticleTitle>
            <Pagination>
                <MedlinePgn>315-25</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Cyproconazole, a triazole fungicide, causes hepatocellular adenomas and carcinomas in CD-1 mice at dose levels of 100 and 200 ppm. The constitutive androstane receptor (CAR) has been shown to play a significant role in the overall mode of action for several nongenotoxic rodent carcinogens such as phenobarbital. The liver effects of dietary cyproconazole or phenobarbital were investigated after 2, 7, or 14 days in male CD-1, C57BL/6J, and C3H/HeNClrBR mice. Cyproconazole produced similar, dose-responsive effects in all three strains of mice, and the response was similar to that of phenobarbital. Subsequently, Car-null and wild-type male mice on a C3H/HeNClrBR background were administered 200 or 450 ppm cyproconazole, or 850 ppm phenobarbital for up to 7 days. In wild-type mice, 200 ppm cyproconazole caused liver hypertrophy, increased liver weight and cell proliferation, single-cell necrosis and fat vacuolation, effects generally similar to those caused by 850 ppm phenobarbital. Plasma cholesterol was decreased by both compounds, but cyproconazole had a greater effect. The higher dose (450 ppm) of cyproconazole caused similar changes, but greater evidence of liver damage was observed, including a large increase in plasma transaminases. Induction of CAR target genes Cyp2b10 and Gadd45beta was observed with both compounds, whereas the cell cycle regulatory gene Mdm2 was unaffected. In Car-null mice, the effects noted with either cyproconazole or phenobarbital were absent or greatly diminished. These experiments demonstrate that short-term liver effects of cyproconazole in mice are CAR-dependent and similar to those of phenobarbital, a known nongenotoxic rodent liver carcinogen.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Peffer</LastName>
                    <ForeName>Richard C</ForeName>
                    <Initials>RC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Syngenta Crop Protection, Inc., Greensboro, North Carolina 27419, USA. richard.peffer@syngenta.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moggs</LastName>
                    <ForeName>Jonathan G</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pastoor</LastName>
                    <ForeName>Timothy</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Currie</LastName>
                    <ForeName>Richard A</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wright</LastName>
                    <ForeName>Jayne</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Milburn</LastName>
                    <ForeName>Gill</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Waechter</LastName>
                    <ForeName>Felix</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rusyn</LastName>
                    <ForeName>Ivan</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>06</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Sci</MedlineTA>
            <NlmUniqueID>9805461</NlmUniqueID>
            <ISSNLinking>1096-0929</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000943">Antigens, Differentiation</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005659">Fungicides, Industrial</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C490125">Gadd45b protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>94361-06-5</RegistryNumber>
                <NameOfSubstance UI="C093628">cyproconazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.-</RegistryNumber>
                <NameOfSubstance UI="D013250">Steroid Hydroxylases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D001189">Aryl Hydrocarbon Hydroxylases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C101679">Cyp2b10 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 6.3.2.19</RegistryNumber>
                <NameOfSubstance UI="C497207">Mdm2 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 6.3.2.19</RegistryNumber>
                <NameOfSubstance UI="D051736">Proto-Oncogene Proteins c-mdm2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YQE403BP4D</RegistryNumber>
                <NameOfSubstance UI="D010634">Phenobarbital</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000943">Antigens, Differentiation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001189">Aryl Hydrocarbon Hydroxylases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004032">Diet</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004790">Enzyme Induction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005234">Fatty Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005659">Fungicides, Industrial</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D022781">Hepatocytes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006984">Hypertrophy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008809">Mice, Inbred C3H</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009929">Organ Size</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010634">Phenobarbital</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051736">Proto-Oncogene Proteins c-mdm2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011944">Receptors, Androgen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013045">Species Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013250">Steroid Hydroxylases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014230">Triazoles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014617">Vacuoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">kfm154</ArticleId>
            <ArticleId IdType="doi">10.1093/toxsci/kfm154</ArticleId>
            <ArticleId IdType="pubmed">17557908</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18072175</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1556-9039</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>3</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medical toxicology : official journal of the American College of Medical Toxicology</Title>
                <ISOAbbreviation>J Med Toxicol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Reversible cardiomyopathy complicating intrathecal baclofen withdrawal: a case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>187-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This case report is about reversible cardiomyopathy associated with intrathecal baclofen withdrawal. Previous literature has reported that enteral baclofen does not adequately control intrathecal baclofen withdrawal. In our case, coronary atherosclerosis did not play a role in the development of the cardiomyopathy. However, reinstitution of intrathecal baclofen promptly resulted in improvement. One could hypothesize that myocardial stunning from sympathetic hyperactivity led to a similar cardiomyopathy reported with catecholamine excess or acute sympathomimetic poisoning.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pizon</LastName>
                    <ForeName>Anthony F</ForeName>
                    <Initials>AF</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Pittsburgh School of Medicine, Division of Medical Toxicology, Pittsburgh, PA, USA. pizonaf@upmc.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lovecchio</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Med Toxicol</MedlineTA>
            <NlmUniqueID>101284598</NlmUniqueID>
            <ISSNLinking>1556-9039</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009125">Muscle Relaxants, Central</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>H789N3FKE8</RegistryNumber>
                <NameOfSubstance UI="D001418">Baclofen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>O26FZP769L</RegistryNumber>
                <NameOfSubstance UI="D008140">Lorazepam</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YI7VU623SF</RegistryNumber>
                <NameOfSubstance UI="D015742">Propofol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1967 Oct 21;2(7521):889</RefSource>
                <PMID Version="1">12389554</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Clin Toxicol. 2003;41(1):83-5</RefSource>
                <PMID Version="1">12645974</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Mol Cell Cardiol. 1985 Apr;17(4):349-59</RefSource>
                <PMID Version="1">4020875</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cardiol. 1989 Dec;12(12):725-7</RefSource>
                <PMID Version="1">2612079</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1991 Mar 6;265(9):1152-4</RefSource>
                <PMID Version="1">1996001</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br Heart J. 1992 Aug;68(2):221-2</RefSource>
                <PMID Version="1">1389744</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Heart J. 1983 Dec;4 Suppl H:43-50</RefSource>
                <PMID Version="1">6662132</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2005 Feb 10;352(6):539-48</RefSource>
                <PMID Version="1">15703419</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cardiol Rev. 2005 Mar-Apr;13(2):69-72</RefSource>
                <PMID Version="1">15705255</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Clin Pharmacol. 2004 Aug 9;4:6</RefSource>
                <PMID Version="1">15301690</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prog Cardiovasc Dis. 1974 Jul-Aug;17(1):73-86</RefSource>
                <PMID Version="1">4599470</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Pathol Lab Med. 1981 Dec;105(12):664-9</RefSource>
                <PMID Version="1">6895456</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Cardiol. 1995 Mar 1;75(7):503-5</RefSource>
                <PMID Version="1">7863998</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001418">Baclofen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009202">Cardiomyopathies</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015918">Infusion Pumps, Implantable</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007278">Injections, Spinal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007441">Intubation, Gastrointestinal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008140">Lorazepam</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009125">Muscle Relaxants, Central</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015742">Propofol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013375">Substance Withdrawal Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3550018</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18072175</ArticleId>
            <ArticleId IdType="pmc">PMC3550018</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1323073</PMID>
        <DateCreated>
            <Year>1992</Year>
            <Month>09</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1992</Year>
            <Month>09</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0931-0509</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1992</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</Title>
                <ISOAbbreviation>Nephrol. Dial. Transplant.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>623-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The effect of bezafibrate, at doses of 200 mg three times weekly throughout a period of 10 weeks, on lipoprotein (a) and triglyceride-rich lipoproteins including intermediate-density lipoproteins (IDL) has been studied in 12 patients with chronic renal failure receiving haemodialysis. No side-effects were observed, and serum creatine phosphate kinase values remained within normal limits throughout the duration of the study. Serum cholesterol, triglycerides and apoprotein (apo) B significantly decreased after bezafibrate, whereas apo A-I increased significantly. Serum lipoprotein (a) decreased after bezafibrate, although differences reached no statistical significance. The very-low-density lipoproteins (VLDL) cholesterol and the VLDL triglycerides decreased from 0.93 +/- 0.45 mmol/l (Mean +/- SD) to 0.54 +/- 0.27 mmol/l (P less than 0.05) and from 1.50 +/- 0.58 mmol/l to 0.91 +/- 0.35 mmol/l (P less than 0.01) respectively. The IDL cholesterol and IDL triglycerides decreased from 0.44 +/- 0.35 mmol/l to 0.20 +/- 0.18 mmol/l (P = NS) and from 0.46 +/- 0.35 mmol/l to 0.17 +/- 0.12 mmol/l (P less than 0.05) respectively. These data, with a substantial improvement of the lipoprotein profile in patients with chronic renal failure on haemodialysis after treatment with bezafibrate, suggest a decrease in the coronary heart disease risk.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pelegrí</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nephrology, Quinta La Salut l'Aliança, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Romero</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sentí</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nogués</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pedro-Botet</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubiés-Prat</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>GERMANY</Country>
            <MedlineTA>Nephrol Dial Transplant</MedlineTA>
            <NlmUniqueID>8706402</NlmUniqueID>
            <ISSNLinking>0931-0509</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053419">Lipoproteins, IDL</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Y9449Q51XH</RegistryNumber>
                <NameOfSubstance UI="D001629">Bezafibrate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001629">Bezafibrate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007676">Kidney Failure, Chronic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008074">Lipoproteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053419">Lipoproteins, IDL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D006435">Renal Dialysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014280">Triglycerides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1323073</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18072171</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1556-9039</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>3</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medical toxicology : official journal of the American College of Medical Toxicology</Title>
                <ISOAbbreviation>J Med Toxicol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Death temporally related to the use of a Beta adrenergic receptor antagonist in cocaine associated myocardial infarction.</ArticleTitle>
            <Pagination>
                <MedlinePgn>169-72</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Although it is commonly stated that the use of beta adrenergic receptor antagonists is contraindicated in patients with cocaine toxicity, actual clinical evidence of harm is lacking. This case helps to highlight the risks of beta adrenergic receptor antagonists in patients with chest pain associated with cocaine use.</AbstractText>
                <AbstractText Label="CASE REPORT" NlmCategory="METHODS">A 54-year-old man was brought to the emergency department (ED) complaining of chest pain after using approximately 1 gram of intranasal cocaine. Aspirin and nitroglycerin spray relieved his pain. Although he remained pain free, tachycardia persisted despite 15 mg of diazepam intravenously. Nearly two hours after presentation, a total of 5 mg of metoprolol was given for persistent tachycardia (115/minute) and an elevated troponin. Shortly thereafter, the patient complained of crushing substernal chest pain, developed pulseless electrical activity, and could not be resuscitated.</AbstractText>
                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The administration of beta adrenergic receptor antagonists exacerbates cocaine-induced lethality in animals. In humans given smaller doses of cocaine, beta adrenergic receptor antagonists exacerbate coronary vasoconstriction. Both effects are presumed to occur through unopposed alpha adrenergic receptor agonism. Despite these data, actual cases describing adverse effects in cocaine users given beta adrenergic receptor antagonists are uncommon. This case supports the potential lethality of a cocaine-beta adrenergic receptor antagonist interaction.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fareed</LastName>
                    <ForeName>Fareed N</ForeName>
                    <Initials>FN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Columbia University Medical Center, NY, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>Gar</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffman</LastName>
                    <ForeName>Robert S</ForeName>
                    <Initials>RS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Med Toxicol</MedlineTA>
            <NlmUniqueID>101284598</NlmUniqueID>
            <ISSNLinking>1556-9039</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GEB06NHM23</RegistryNumber>
                <NameOfSubstance UI="D008790">Metoprolol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Heart Circ Physiol. 2000 Jul;279(1):H1-6</RefSource>
                <PMID Version="1">10899035</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Crit Care Med. 1999 Apr;27(4):784-9</RefSource>
                <PMID Version="1">10321670</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Emerg Med. 2001 Apr;37(4 Suppl):S78-90</RefSource>
                <PMID Version="1">11290973</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2001 Aug 2;345(5):351-8</RefSource>
                <PMID Version="1">11484693</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2001 Oct 20;358(9290):1368</RefSource>
                <PMID Version="1">11684248</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1976 Sep 18;2(7986):640-1</RefSource>
                <PMID Version="1">61383</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Toxicol. 1977;10(3):265-71</RefSource>
                <PMID Version="1">862360</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Toxicol. 1978;13(2):325-32</RefSource>
                <PMID Version="1">737989</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Toxicol. 1980 Jun;16(4):499-508</RefSource>
                <PMID Version="1">7408425</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1981 May;217(2):350-6</RefSource>
                <PMID Version="1">7229977</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Emerg Med. 1988 Mar;17(3):282-3</RefSource>
                <PMID Version="1">3345023</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1989 Dec 7;321(23):1557-62</RefSource>
                <PMID Version="1">2573838</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med. 1990 Apr;88(4):325-31</RefSource>
                <PMID Version="1">2327419</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1990 Jun 15;112(12):897-903</RefSource>
                <PMID Version="1">1971166</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Emerg Med. 1991 Mar;9(2):161-3</RefSource>
                <PMID Version="1">1671639</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1992 Apr 1;116(7):556-61</RefSource>
                <PMID Version="1">1543310</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med. 1993 Jun;94(6):608-10</RefSource>
                <PMID Version="1">8506886</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Emerg Med. 1994 Jul-Aug;12(4):485-90</RefSource>
                <PMID Version="1">7963395</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Crit Care Med. 1999 Apr;27(4):688-9</RefSource>
                <PMID Version="1">10321652</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2001 Jan 30;103(4):502-6</RefSource>
                <PMID Version="1">11157713</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000281">Administration, Intranasal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000319">Adrenergic beta-Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002423">Cause of Death</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008790">Metoprolol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009203">Myocardial Infarction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014661">Vasoconstriction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014662">Vasoconstrictor Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3550023</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18072171</ArticleId>
            <ArticleId IdType="pmc">PMC3550023</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9265840</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>10</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>10</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0379-8046</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>43</Volume>
                    <PubDate>
                        <Year>1996</Year>
                    </PubDate>
                </JournalIssue>
                <Title>The South African journal of communication disorders. Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings</Title>
                <ISOAbbreviation>S Afr J Commun Disord</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ototoxicity of aminoglycoside drugs in tuberculosis treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The possible ototoxic effect of kanamycin, streptomycin and a standard anti-TB drug combination, used in the treatment of 92 TB patients (7-71 years old), was examined by measuring the highest audible electric bone conduction frequency before and after treatment, using an Audimax 500 audiometer. At the so-called &quot;safe&quot; levels of drug administration it was found that kanamycin was markedly ototoxic, streptomycin very slightly ototoxic and the standard anti-TB drug combination had practically no ototoxic effect. Furthermore, it was found that none of these drugs were gender specific. Lastly, the possible effects of ageing on highest audible bone conduction frequency is discussed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Voogt</LastName>
                    <ForeName>G R</ForeName>
                    <Initials>GR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department Otorhinolaryngology, Medical University of Southern Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schoeman</LastName>
                    <ForeName>H S</ForeName>
                    <Initials>HS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>SOUTH AFRICA</Country>
            <MedlineTA>S Afr J Commun Disord</MedlineTA>
            <NlmUniqueID>7805099</NlmUniqueID>
            <ISSNLinking>0379-8046</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>59-01-8</RegistryNumber>
                <NameOfSubstance UI="D007612">Kanamycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Y45QSO73OB</RegistryNumber>
                <NameOfSubstance UI="D013307">Streptomycin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000995">Antitubercular Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006316">Hearing Loss, High-Frequency</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007612">Kanamycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013307">Streptomycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014376">Tuberculosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1996</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1996</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1996</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9265840</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1009381</PMID>
        <DateCreated>
            <Year>1977</Year>
            <Month>03</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1977</Year>
            <Month>03</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-1447</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2</Volume>
                    <Issue>6049</Issue>
                    <PubDate>
                        <Year>1976</Year>
                        <Month>Dec</Month>
                        <Day>11</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British medical journal</Title>
                <ISOAbbreviation>Br Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phenformin as a cause of primary pulmonary hypertension.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1450</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fahlèn</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br Med J</MedlineTA>
            <NlmUniqueID>0372673</NlmUniqueID>
            <ISSNLinking>0007-1447</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>DD5K7529CE</RegistryNumber>
                <NameOfSubstance UI="D010629">Phenformin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br Heart J. 1973 Aug;35(8):824-8</RefSource>
                <PMID Version="1">4729840</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Presse Med. 1970 Jan 3;78(1):23-6</RefSource>
                <PMID Version="1">4985361</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006976">Hypertension, Pulmonary</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010629">Phenformin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1690408</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1976</Year>
                <Month>12</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1976</Year>
                <Month>12</Month>
                <Day>11</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1976</Year>
                <Month>12</Month>
                <Day>11</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1009381</ArticleId>
            <ArticleId IdType="pmc">PMC1690408</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
